Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact email@example.com.
A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with BAN2401, an Anti-Aβ Protofibril Antibody
40 Pages Posted: 29 Sep 2020More...
Background: BAN2401, an IgG1 monoclonal antibody, selectively targets soluble aggregated amyloid beta (Aβ), with activity across oligomers, protofibrils and insoluble fibrils. BAN2401-G000-201, a randomized double blind clinical trial, utilized a Bayesian design with response-adaptive randomization to assess 3 doses across 2 regimens of BAN2401 versus placebo in early Alzheimer’s disease (EAD).
Methods: BAN2401-G000-201 aimed to establish the effective dose 90% (ED90), defined as the simplest dose that achieves ≥90% of the maximum treatment effect. The Primary endpoint was Bayesian analysis of 12-month clinical change on the Alzheimer’s Disease Composite Score (ADCOMS) for the ED90 dose, which required an 80% probability of ≥25% clinical slowing versus placebo. Key secondary endpoints included 18-month Bayesian and frequentist analyses of brain amyloid reduction using positron emission tomography; clinical decline on ADCOMS, Clinical Dementia Rating-Sum-of-Boxes (CDR-SB), and Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog14); changes in CSF core biomarkers; and total hippocampal volume (HV) using volumetric magnetic resonance imaging.
Findings: 854 randomized subjects were treated (BAN2401:609; placebo:245). At 12 months, the 10-mg/kg biweekly ED90 dose showed a 64% probability to be better than placebo by 25% on ADCOMS, which missed the 80% threshold for the primary outcome . At 18 months, 10-mg/kg biweekly BAN2401 reduced brain amyloid (-0.306 SUVr units) while slowing clinical decline by 27% and 30% on ADCOMS, 56% and 47% on ADAS-cog14 and 33% and 26% on CDR-SB versus placebo according to Bayesian and frequentist analyses, respectively. CSF biomarker and HV results were supportive of treatment effect. BAN2401 was well-tolerated with 9.9% incidence of amyloid-related imaging abnormalities-edema/effusion at 10-mg/kg biweekly.
Interpretation: BAN2401-G000-201 did not meet the 12-month Primary endpoint. However, prespecified 18-month Bayesian and frequentist analyses demonstrated reduction in brain amyloid accompanied by a consistent slowing of clinical decline across several clinical and biomarker endpoints. A Phase 3 study (ClarityAD) in EAD is underway.
Trial Registration: Clinical Trials.gov: NCT01767311.
Funding Statement: This trial was funded by Eisai Inc.
Declaration of Interests: CJS, YZ, SD, JW, JK, RYKL, HB, MR, AK, LR, RG, and LDK are employees of Eisai. LL is an employee of BioArctic. DAB and SB are employees of Berry Consultants.JLC provided consultation to the following pharmaceutical companies: Acadia, Accera, Actinogen, ADAMAS, Alkahest, Allergan, Alzheon, Avanir, Axovant, Axsome, BiOasis Technologies, Biogen, Eisai, Genentech, Grifols, Kyowa, Lilly, Lundbeck, Merck, Nutricia, Otsuka, QR Pharma, Resverlogix, Roche, Samus, Servier, Suven, Takeda, Toyoma, and United Neuroscience companies
Ethics Approval Statement: The trial was approved by the institutional review board or independent ethics committee at each center and all patients provided informed consent.
Keywords: Alzheimer's disease, BAN2401, clinical trial, biomarker, ADCOMS, amyloid PET, neurofilament light, neurogranin, p-tau
Suggested Citation: Suggested Citation